Clinical Trials Logo

Clinical Trial Summary

Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. For clinical operationalization, organ dysfunction can be represented by an increase in the Sequential Organ Failure Assessment (SOFA) score of 2 points or more, which is associated with an in-hospital mortality greater than 10%. pancreatic stone protein has been studied as biomarker of sepsis and results suggests that it has higher diagnostic performance. The main objective of this study is to identify ability of pancreatic stone protein (PSP) as a new biomarker for diagnosis of urosepsis in Intensive Care Units comparison to other biomarkers and its role as a prognostic marker for mortality


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06090526
Study type Observational
Source Ain Shams University
Contact
Status Not yet recruiting
Phase
Start date May 1, 2024
Completion date March 31, 2025